Brief: Longboard Pharmaceuticals Announces Positive Topline Data From The Pacific Study
02/01/2024 13:18
Jan 2 (Reuters) - Longboard Pharmaceuticals Inc
LBPH.O :
* LONGBOARD PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA
FROM
THE PACIFIC STUDY, A PHASE 1B/2A CLINICAL TRIAL, FOR BEXICASERIN
(LP352) IN PARTICIPANTS WITH DEVELOPMENTAL AND EPILEPTIC
ENCEPHALOPATHIES (DEES)
* BEXICASERIN ACHIEVED MEDIAN SEIZURE REDUCTION OF 53.3% IN
COUNTABLE MOTOR SEIZURES
* BEXICASERIN EXHIBITED FAVORABLE SAFETY AND TOLERABILITY
RESULTS
Source text for Eikon: ID:nBw55jk6Ja
Further company coverage: LBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions